SNY Jun 2024 47.500 call
| Previous close | 1.7500 |
| Open | 2.0000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 47.50 |
| Expiry date | 2024-06-21 |
| Day's range | 1.7500 - 2.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- GuruFocus.com
Novavax Inc (NVAX) (Q1 2024) Earnings Call Transcript Highlights: Strategic Partnerships and ...
Discover how Novavax Inc (NVAX) is reshaping its future with significant Sanofi collaboration and revised financial projections in Q1 2024.
GlobeNewswireDupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately controlled CRSwNP, a condition driven in part by underlying type 2 inflammation that obstructs the sinuses and nasal passages and can lead to a loss of sense of smell Current treatment options for adolescents with CRSwNP leave many patients with uncontrolled disease and often result in the recurrence of nasal polyps TARRYTOWN, N.Y. and PARIS, May 13, 2024 (GLOBE NEWSWIRE) -
GlobeNewswirePress Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty
Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty Paris, May 13, 2024. As the largest private contributor to the security and independence of France's health ecosystem, Sanofi today announces an investment of more than €1 billion to create new bioproduction capacity at its sites in Vitry-sur-Seine (Val de Marne), Le Trait (Seine-Maritime) and Lyon Gerland (Rhône). This new investment will create more than
